ijms-logo

Journal Browser

Journal Browser

Oral Potentially Malignant Disorders and Oral Cancers: From Molecular Pathology to Therapeutic Approaches

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 November 2025) | Viewed by 683

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Titu Maiorescu University, 031593 Bucharest, Romania
2. Department of Oral and Maxillofacial Surgery, Carol Davila Central Military Emergency Hospital, 010825 Bucharest, Romania
Interests: head and neck cancer; prognostic biomarkers; carcinogenesis; imaging; inflammation; salivary
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Head and Neck Surgery, University College London Hospital (UCLH), London, UK
Interests: head and neck cancer; craniofacial; soft tissue and skeletal injuries to the face, head and neck

Special Issue Information

Dear Colleagues,

Oral cancer remains a significant global health challenge, with a major negative impact, particularly in regions with limited access to early detection and care. Despite advancements in diagnosis and treatment, survival rates show modest improvements, underscoring the urgent need for a deeper molecular understanding and innovative therapeutic strategies. A critical step toward improving patient outcomes lies in the precise identification and understanding of premalignant lesions, their progression to malignancy, and the molecular mechanisms driving this transformation.

This Special Issue of the International Journal of Molecular Sciences aims to bring together cutting-edge research focused on the molecular pathology of oral potentially malignant disorders (OPMDs) and oral cancer, along with translational approaches that can promote innovation in therapy. Our goal is to provide a platform for researchers, clinicians, and translational scientists to share insights that bridge the gap between molecular science and clinical application, ultimately fostering the development of more effective, personalized approaches to oral cancer prevention and treatment.

We warmly invite clinicians, researchers, and interdisciplinary teams to contribute to this Special Issue and help shape the future of oral cancer management. Original research articles, comprehensive reviews, and short communications that explore molecular biomarkers, signaling pathways, proteomic and genomic alterations, tumor microenvironments, immune responses, microbiota, and the development of novel diagnostic or therapeutic strategies are all welcomed for evaluation in our Special Issue. By bridging fundamental science and translational innovation, this collection seeks to advance precision medicine approaches and improve outcomes for patients with oral cancer.

Prof. Dr. Ana Caruntu
Dr. Nicholas Kalavrezos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oral cancer
  • oral potentially malignant disorders
  • molecular mechanisms in oral cancer
  • detection of oral cancer
  • pathogenic mechanisms of oral cancer
  • immune system
  • translational oral cancer
  • microbiota oral cancer
  • therapy for oral cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2126 KB  
Article
Naltrexone Has Variable and Schedule-Dependent Effects on Oral Squamous Cell Carcinoma Cells
by Sahar Kazmi, Erica Sanford, Zaid A. Rammaha, Ethan J. Bengson, Feng Gao, Linda Sangalli and Cai M. Roberts
Int. J. Mol. Sci. 2025, 26(21), 10651; https://doi.org/10.3390/ijms262110651 - 1 Nov 2025
Viewed by 471
Abstract
Oral squamous cell carcinoma (OSCC) is marked by profound differences in survival between the localized and disseminated disease, estimated to result in a 70% and less than a 40% five-year survival rate with surgical and/or radiation approaches (in localized cases) and chemotherapy (in [...] Read more.
Oral squamous cell carcinoma (OSCC) is marked by profound differences in survival between the localized and disseminated disease, estimated to result in a 70% and less than a 40% five-year survival rate with surgical and/or radiation approaches (in localized cases) and chemotherapy (in metastatic cases), respectively. Given the suboptimal efficacy of current management options, new therapeutic approaches are needed to supplement existing chemotherapies and improve outcomes. One emerging therapeutic option is naltrexone (NTX), an opioid antagonist that has shown promising outcomes at low doses in other forms of cancer. This study sought to determine the effectiveness of intermittent dosing of naltrexone on oral cancer cell survival, either as a single agent or in combination with traditional chemotherapy. Two human OSCC lines (locally invasive SCC-25 and metastatic Detroit 562) were cultured. Cells were exposed to 1 µM and 10 µM NTX alone, using intermittent (5 h once, 5 h daily, 5 h every other day) or constant 72 h exposure. Cells were exposed to combination therapy with cisplatin or docetaxel under three NTX regimens (5 h, 24 h, and continuous). Cell viability was determined using Sulphorhodamine B (SRB) assay and Cell Counting Kit-8 (CCK-8). Differences across treatments were assessed using ANOVA (p < 0.05). The effect of low-dose NTX alone, across varying treatment regimens, did not yield significant, consistent changes in OSCC cell survival. Combination with cytotoxic drugs reduced cell viability more efficiently than chemotherapy alone at select doses, particularly through intermittent short-term pretreatment schedules, but the full dose response demonstrated antagonism between NTX and chemotherapy, independent of the dosing schedule. These results contrast with previous findings in other cancers, and, thus, further study and optimization will be needed to determine the clinical benefit and reproducibility of these findings. Full article
Show Figures

Figure 1

Back to TopTop